Arterial-portal fistula treated with hepatic arterial embolization and portal venous aneurysm stent-graft exclusion complicated by type 2 endoleak. by Bremer, William A et al.
UCSF
UC San Francisco Previously Published Works
Title
Arterial-portal fistula treated with hepatic arterial embolization and portal venous 


















eScholarship.org Powered by the California Digital Library
University of California
R a d i o l o g y  Ca s e  R e p o r t s  1 4  ( 2 0 1 9 )  1 3 0 1 – 1 3 0 5  
Available online at www.sciencedirect.com 
journal homepage: www.elsevier.com/locate/radcr 
Case Report 
Arterial-portal fistula treated with hepatic arterial 
embolization and portal venous aneurysm 
stent-graft exclusion complicated by type 2 
endoleak 
William A. Bremer, MD a , R. Peter Lokken, MD, MPH b , ∗, Ron C. Gaba, MD, MS a , 
James T. Bui, MD a 
a Department of Radiology, Division of Interventional Radiology, University of Illinois Health. 1740 W. Taylor St. MC 
931 Chicago, IL 60612, USA 
b Department of Radiology and Biomedical Imaging, Division of Interventional Radiology, University of California, 
San Francisco. 505 Parnassus Avenue M-361 San Francisco, CA 94143, USA 
a r t i c l e i n f o 
Article history: 
Received 29 June 2019 
Revised 31 July 2019 
Accepted 2 August 2019 
Available online 20 August 2019 
Keywords: 
Arterial-portal fistula 
Portal vein aneurysm 
Type 2 endoleak 
a b s t r a c t 
Intrahepatic arterioportal fistulas may be complicated by portal hypertension. An associated 
portal venous aneurysm (PVA) may impinge upon adjacent structures or rupture. We present 
a 65-year-old man with an intrahepatic Intrahepatic arterioportal fistula and 6.4 × 5.8 cm 
right portal vein aneurysm extending within 0.4 cm of the hepatic margin, associated with 
pain concerning for impending rupture. The PVA was refractory to transarterial emboliza- 
tion due to recruitment of arterial collaterals. Therefore, it was additionally excluded from 
the portal vein with a 12 mm × 9.5 cm venous stent graft. Although endovascular ther- 
apy thrombosed the aneurysm and improved symptoms, it was complicated by a type 2 
endoleak into the PVA. 
© 2019 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license. 











Intrahepatic arterioportal fistulas (APFs) may be congenital
or acquired from cirrhosis, trauma, surgery, or percutaneous
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can be complicated by symptoms of portal hypertension.
Progressive enlargement and development of a portal venous
aneurysm (PVA) may lead to compression of biliary ducts
and other adjacent structures, or rupture [1] . Transarterial
embolization (TAE) has been described in treatment of APF
but may be ineffective due to recruitment of collateral arterialniversity of Washington. This is an open access article under the 
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 perfusion [2] . We describe a case of an APF complicated by a
large PVA refractory to TAE alone and ultimately treated with
combined TAE and portal venous stent-graft exclusion. En-
dovascular therapy thrombosed the aneurysm, ameliorated
symptoms, and reduced aneurysm size, but was complicated
by type 2 endoleak. This case highlights the limitations of
arterial coil embolization alone for the treatment of complex
vascular lesions. 
Case report 
Our institutional review board does not require approval for
single retrospective case reports. A 65-year-old man with a
history of hepatitis C virus cirrhosis and orthotopic liver trans-
plantation (OLT) 16 years prior developed right upper quadrant
abdominal pain. He underwent contrast-enhanced magnetic
resonance imaging at an outside hospital to further evaluate a
PVA initially detected on ultrasound (US). MRI demonstrated
arterial-phase enhancement of the right portal vein and
peripheral parenchymal enhancement suggestive of APF,
with an associated 6.4 ×5.8 cm PVA arising from the origin of
the right portal vein and involving the anterior and posterior
branches ( Fig. 1 A). The aneurysm extended to within 0.4 cm of
the hepatic margin. Review of previous imaging demonstrated
a small, peripheral APF on a CT scan performed in 2003 with
enlargement to 3.7 ×3.5 cm on a CT scan performed in 2007;
the fistula was at the site of prior percutaneous liver biopsy. 
The enlargement of the aneurysm, proximity to the liver
capsule, and associated pain raised concern for impend-
ing rupture. Multidisciplinary review including Hepatology,
Surgery, and Interventional Radiology concluded that right
hepatectomy was undesirable due to scarring from previous
OLT and small future liver remnant volume; therefore, the de-
cision was made to perform arteriography with intention of
TAE to close the APF, with concurrent listing for second OLT
due to concern for precipitating hepatic decompensation and
biliary ischemia. At arteriography, a hypertrophied right hep-
atic artery (RHA) was identified with contributors arising from
all segmental arterial branches of the RHA to the PVA. Em-
bolization of posterior subsegmental branches with 0.018-inch
Nester coils (Cook Medical, Bloomington, IN) resulted in de-
creased but persistent perfusion from additional branches of
the RHA ( Fig. 1 B). 
A subsequent embolization procedure targeted additional
RHA subsegmental branches in the same fashion; however,
new perfusion to the PVA developed from branches of the LHA
( Fig. 1 C). Given the failure of durable occlusion with coil em-
bolization, additional embolization was performed of subseg-
mental arterial branches of the segments II, III, and IV arteries
with N-butyl cyanoacrylate (NBCA, Trufill, Cordis Neurovascu-
lar Inc., Miami Lakes, FL) in a ratio of 1:3 with ethiodized oil
(Lipiodol; Guerbet LLC, Princeton, NJ) and resulted in complete
occlusion of the arterial supply to the PVA on angiography. 
With occlusion of the arterial supply to the PVA achieved,
the decision was made to pursue exclusion of the PVA to
achieve thrombosis and reduction in size. A multidisciplinary
review was held and the decision was made to pursue stent-
graft exclusion of the PVA. Diagnostic mapping of the PVA andportal vein was initially performed. The left portal vein was
accessed under US guidance with a 21-gauge needle and an
Accustick (Boston Scientific, Marlborough, MA) was utilized to
accommodate a 0.035-inch guidewire. A 6-French sheath was
then placed, and a 5-French pigtail marking catheter advanced
into the main portal vein. Portal venous pressure measured 15
mm Hg. On portal venography the PVA involved the entire RPV,
with 2.2 cm diameter at its origin and enlarging over a short
segment to 6.8 cm ( Fig. 1 D). The left portal vein landing zone
measured 1.5 cm in diameter and the main portal vein land-
ing zone measured 1.8 cm. Given the large caliber of the left
portal vein, placement of a standard stent graft was not feasi-
ble, and as such an iliac limb endoprosthesis was selected for
use. 
The 6-French sheath was exchanged for a 12-French GORE
DrySeal Flex Introducer Sheath (GORE Medical, Newark, DE). A
20 mm × 9.5 cm GORE Excluder Contralateral Leg Endopros-
thesis (PLC 201000, GORE Medical, Newark, DE) was reverse-
loaded [3] into the sheath to deploy the 20 mm aspect in the
main portal vein and the 16 mm end in the left portal vein.
The stent graft was apposed to the main and left portal veins
with a compliant Q50 Plus Stent Graft Balloon Catheter (GORE
Medical, Newark, DE). Following stent-graft placement, portal
venography demonstrated no enhancement of the excluded
aneurysm ( Fig. 1 E), and immediate thrombosis was observed
of the PVA on US. Portal venous pressure measured 17 mm Hg.
Microfibrillar collagen paste (Avitene; CR Bard, Murray Hill, NJ)
was prepared by mixing the dry flour with 3 mL of iodinated
contrast material (Omnipaque-300, GE Healthcare, Chicago, IL)
and 3 mL of normal saline. The sheath was withdrawn into
the hepatic parenchymal tract and an 8-French sheath was
advanced into the 12-French sheath; the track was embolized
with microfibrillar collagen paste through the 8-French sheath
under fluoroscopic guidance [4] . US 1 week later demonstrated
echogenic thrombus and no Doppler signal within the PVA;
the stent graft and LPV remained patent. Abdominal pain had
resolved, and liver function tests remained normal. 
A CT performed 3 months later showed that the PVA had
decreased in size to 4.5 ×4.4 cm. However, peripheral en-
hancement within the PVA in the arterial phase suggested
new arterial-portal shunts. Five months after stent-graft ex-
clusion, the patient developed atrial fibrillation associated
with a new pericardial effusion attributed to a viral infec-
tion, and anticoagulation was initiated with warfarin. On CT
follow-up at 6 months, the PVA remained 4.5 ×4.4 cm in di-
ameter but with increased peripheral enhancement ( Fig. 1 F).
Angiography confirmed a type 2 endoleak supplied by new
branches of the segment 4 hepatic artery, reconstituting
branches of the RHA distal to coils ( Fig. 1 G). 
Given the extensive network of perfusing arteries refrac-
tory to prior embolization, decreased size of the aneurysm,
and resolution of symptoms, further endovascular therapy
was withheld. CT follow-up at 11 months demonstrated sta-
ble size of the PVA with further increase in peripheral en-
hancement. The patient was listed for OLT due to exhaustion
of all endovascular treatment options for the PVA. A donor
liver was procured and retransplantation was performed 14
months after stent-graft exclusion. During transplant, the por-
tal vein was transected and the stent graft was extracted
prior to creation of an end-to-end donor-recipient portal vein
R a d i o l o g y  Ca s e  R e p o r t s  1 4  ( 2 0 1 9 )  1 3 0 1 – 1 3 0 5  1303 
Fig. 1 – Images of a 65-year-old man status post-OLT 16 years prior with abdominal pain. (A) Axial contrast-enhanced MR 
image demonstrates arterial-phase enhancement of the right portal vein with an associated 6.4 ×5.8 cm PVA (arrow). (B) 
Celiac angiography following coil embolization of multiple subsegmental RHA contributors shows persistent perfusion of 
the PVA (arrow) via additional branches of the RHA. (C) On angiography 1 month later, collateral reconstitution (arrows) of 
RHA branches have developed from the LHA. (D) Portal venography 4 months after initial angiography opacifies the right 
PVA with origin (arrow) measuring 2.2 cm in diameter. (E) Following stent-graft placement portal venography confirms 
exclusion of the PVA with preserved flow within the superior mesenteric vein and left portal vein. (F) Axial 
contrast-enhanced CT image 6 months after stent-graft exclusion demonstrates arterial-phase peripheral enhancement of 
the PVA (arrows). (G) Subsequent angiography confirmed a type 2 endoleak supplied by branches of the segment 4 hepatic 
artery (black arrow) reconstituting branches of the RHA distal to coils (white arrow). (H) Representative gross pathologic 






 anastomosis. Gross pathology of the explanted liver demon-
strated cirrhotic morphology and a PVA containing organiz-
ing thrombus with multiple vessels adjacent to the PVA, some
containing coils from prior embolization ( Fig. 1 H). The patient
is currently alive 6 months post-transplant. Discussion 
This case demonstrates the difficulty of endovascular treat-
ment of a complex APF with associated PVA, and the
























































































 limitations of treatment by TAE alone due to recruitment
of perfusion by arterial collaterals. 
A proposed classification of arterial portal fistulae by Guz-
man et al categorized APFs into 3 types based on etiology [5] .
The current case describes an example of a Type II fistula, de-
fined as an acquired large central fistula, resulting in an ex-
panding PVA. APFs are not uncommon in liver transplant re-
cipients; in post-transplant patients undergoing hepatic an-
giography, the incidence of APFs has been reported as high as
5.4% [6] . However, in a retrospective audit of 1992 cadaveric
and living donor liver transplant recipients performed over a
13-year period, only 0.2% were found to have hemodynam-
ically significant APFs resulting in liver function test abnor-
malities, suggesting that the majority of APFs do not cause
adverse sequelae [7] . 
If small and peripherally located, an APF is likely to resolve
spontaneously within 1-3 months [5,8] . When large and more
centrally located, as in the current case, APFs are unlikely
to resolve and are likely to become symptomatic [5,9] . While
management in prior decades has been surgical, involving lig-
ation of the involved hepatic artery, resection, or retransplan-
tation [10] , hepatic artery embolization has become the ac-
cepted initial treatment of choice for APFs with a reported
clinical success rate of 83% (15 of 18 patients) in prior case
series [2,9,11–13] . Previously described arterial embolization
interventions for APFs include Amplatzer plugs, coils, detach-
able balloons, NBCA, and sclerotherapy, with agent selection
tailored to the anatomy and complexity of the shunt [9,11] . 
Hepatic arterial embolization may fail to durably occlude
an APF, particularly if supplied by multiple arterial branches.
Wada et al described a small PVA supplied by multiple feed-
ing arteries, with persistent APF despite 2 TAE procedures
with NBCA and ethiodized oil [2] . The fistula was ultimately
treated successfully with retrograde transvenous obliteration
with ethanol and ethiodized oil, with a balloon-mounted
catheter inflated within the segment VIII portal vein outflow
of the APF; concurrently a balloon-mounted catheter was
inflated within the RHA. In the current case, coil embolization
prompted recruitment of collateral circulation to the APF/PVA
complex. Failure was attributed in part to the inability to
position coil packs sufficiently adjacent to the fistulous
connection, as evidenced by reperfusion of the fistula distal
to coils on subsequent angiography. Complete closure was
achieved after embolization with NBCA and ethiodized oil.
These findings suggest that preferential consideration should
be given to liquid embolics over metallic coils in APF treat-
ment, particularly if coils cannot be placed directly adjacent
to the fistulous connection. 
Embolization of the PVA, or balloon-occluded retrograde
transvenous obliteration of the PVA and APF as described by
Wada et al, was anatomically infeasible due to the size and
configuration of the PVA. Stent-graft exclusion was therefore
performed after embolizing the hepatic arterial inflow. This
procedure achieved clinical goals of reduction of the PVA size
and resolution of symptoms, and initially achieved thrombo-
sis of the APF and PVA. However, complete APF occlusion was
transient with development of a type 2 endoleak 3 months
after stent-graft exclusion of the PVA. Warfarin therapy has
been associated with reduced rates of spontaneous thrombo-
sis of type 2 endoleaks [14] and may be a contributing factor topersistence of the endoleak in the presented case. Although
occlusion of RHA branches and the portal vein may elevate
risk for hepatic decompensation or biliary ischemia, these se-
quelae did not occur, likely because of collateral hepatic artery
recruitment visualized on imaging follow-up after stent-graft
placement. 
The literature regarding the management of type 2 en-
doleaks is largely confined to complications following en-
dovascular aortic repair [15,16] , with treatment generally re-
served for patients with growth of the excluded aneurysm sac.
With no reported literature regarding an intrahepatic type 2
endoleak, the risk of late rupture relative to an aortic type
2 endoleak is unknown but may be catastrophic as the liver
is surrounded predominantly by the peritoneal space. Con-
versely the likelihood of success of additional percutaneous
intervention, such as direct sac puncture and embolization
[16] and risk of resulting hepatic infarction and failure, are un-
known. Given reduction of sac size from baseline and resolu-
tion of symptoms following stent graft exclusion, additional
endovascular treatment was deferred in favor of active clini-
cal and imaging surveillance and listing for a second OLT. The
patient remained clinically asymptomatic until the time of
OLT at 14 months following stent-graft exclusion of the PVA,
although follow-up CT examinations had confirmed recruit-
ment of new contributing vessels. 
Conclusion 
Although a complex hepatic APF with associated PVA is rarely
encountered, the principles and techniques used for treat-
ment in this case can be translated to similar lesions in differ-
ent clinical scenarios. Importantly, the limitations of coil TAE
alone are made apparent by the rapid recruitment of perfusion
by arterial collaterals, and preferential consideration should
be given for glue embolization in analogous lesions. Addition-
ally, stent grafts may be successfully employed for aneurysm
exclusion, even using endoprostheses designed for other ap-
plications. 
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